Award for the DZG magazine SYNERGIE
The SYNERGIE magazine of the German Centers for Health Research has won the Berlin Type silver award. The Berliner Type competition honors the best print products from Germany, Austria and Switzerland.
The SYNERGIE magazine of the German Centers for Health Research has won the Berlin Type silver award. The Berliner Type competition honors the best print products from Germany, Austria and Switzerland.
Specific immune cells are less abundant in children with allergic asthma than in healthy individuals.
Prof. Dr. Dr. Friedrich Grimminger was awarded the Von Behring Röntgen Research Medal for his life's work, and Dr. Niklas Gremke received a Von Behring Röntgen Young Investigator Award.
Scientists of the DZL site network UGMLC have discovered that the substance thapsigargin inhibits the proliferation of SARS-CoV-2.
The "Förderpreis für Allergen Immuntherapie" awarded by the German Society for Allergology and Clinical Immunology (DGAKI), goes this year to the DZL scientist Dr. Ulrich Zißler.
The Academy of Sciences in Hamburg honors Fabian Theis as a pioneer in the field of artificial intelligence in biomedical applications, especially in the area of single cell biology.
The German Federal Ministry of Education and Research (BMBF) is strengthening research into the long-term effects of COVID-19 from a total of ten research projects. Among them are two research projects led by DZL scientists.
Could the anti-IL-33 monoclonal antibody Itepekimab be a therapeutic option for moderate to severe chronic obstructive pulmonary disease (COPD)?
An interview with Professor Susanne Herold from the DZL site UGMLC about the Corona vaccination and the current situation in hospitals has been published in the FAZ.
Pulmonary hypertension is a common co-morbidity of COPD. Previous studies have already established that (in the experimental model) pulmonary vascular changes precede the development of emphysema.
Regular examination of the lungs using magnetic resonance imaging (MRI) can detect how lung disease develops in children with cystic fibrosis.
A clinical trial has shown that a triple combination therapy consisting of three known compounds is both safe and effective in cystic fibrosis patients with relatively rare disease-causing genetic defects.
Our site uses cookies and similar technologies. By using the site, you consent to the use of cookies.
You can find more information on this in our Privacy Policy.